Dr. Andria Ford presented “Cerebral oxygen extraction predicts brain lesion progression in Retinal Vasculopathy with Cerebral Leukocencephalopathy, a monogenic microvasculopathy” at the Rare Diseases Day Symposium 2024 in EPNEC at Washington University School of Medicine.
Category: RVCL-S Center Update
New publication quantifying RVCL disease progression (Links to an external site)
Drs. Wilson Wang and Rajendra Apte and colleagues publish novel insights into the quantifying RVCL disease progression using OCT, OCT-A, and FA: “Multimodal Structural and Functional Characterization of Retinal Vasculopathy with Cerebral Leukoencephalopathy” in Ophthalmology Retina.
2021 ClayCo Foundation Innovation Research Awards
Congratulations to the four scientists and their teams who recently were awarded two-year grants by the Clayco Foundation for RVCL research projects. One theme of these new grants is development of model systems that are critical to determining how cells are damaged by RVCL. A model system also will greatly help development and assessment of new RVCL therapeutics. […]
12th Annual Cure CRV Golf Classic
With social distancing and other precautions, the 12th Annual Cure CRV Golf Classic was held by the Morey Family and Friends in Bentonville, Arkansas. All proceeds help fund CRV (RVCL) research at Washington University School of Medicine.We thank the Morey family and friends!!
RVCL Center Family Meeting and Videos
We thank everyone who attended our half day family meeting held Saturday August 26, 2017. This educational meeting summarized new research studies, provided updated information about the recently begun clinical therapeutic trial, and offered advice about genetic testing, prenatal diagnosis and alternative reproductive strategies. You can watch each presentation that was made at the family […]
First clinical trials begun
The first clinical trial utilizing Aclarubicin for treatment of RVCL commenced December 5, 2016 at Washington University School of Medicine. Two patients initially received infusions of Aclarubicin for four consecutive days with blood work and other testing prior to and at the conclusion of the infusion. The study will be conducted for up to two […]